Search

Displaying results 3491 - 3500 of 10000 in total
  1. Drug

    Azadirachtin

    go.drugbank.com/drugs/DB19419
    Investigational

    Azadirachtin is under investigation in clinical trial NCT06617026 (Short-term Outcome of Medical vs. Surgical Management of Chronic Anal Fissure).

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Methotrimeprazine

    go.drugbank.com/drugs/DB01403
    Approved

    It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine.

    Synonyms: (-)-(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amineProducts: LEVOMEPROMAZIN-NX 25 MG/ML, LEVOMEPROMAZIN-NX 40 MG/ML
  3. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. … Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO.

  4. Drug

    Cerulenin

    go.drugbank.com/drugs/DB01034
    Experimental

    It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus. … In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity.

  5. Drug

    Isoflavone

    go.drugbank.com/drugs/DB12007
    ApprovedInvestigationalWithdrawn

    Soybean is an exceptionally rich source of dietary isoflavones, where the average isoflavone content is 1-2 mg/gram [A33103]. … Isoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation.

  6. Drug

    ILY101

    go.drugbank.com/drugs/DB05059
    Investigational

    ILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs. … ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate.

  7. Drug

    Alfimeprase

    go.drugbank.com/drugs/DB04919
    Investigational

    It is a small protein that contains 203 residues (Randolph et al. 1992). Alfimeprase is being developed by Nuvelo. … Alfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (<i>Agkistrodon contortrix contortrix</i>).

  8. Drug

    Urea

    go.drugbank.com/drugs/DB03904
    ApprovedInvestigational

    It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. … A compound formed in the liver from ammonia produced by the deamination of amino acids.

    Products: EXCİPİAL LİPO % 4 EMÜLSİYON, 200 ML, EXCİPİAL HYDRO % 2 EMÜLSİYON, 200 ML
  9. Drug

    Vindesine

    go.drugbank.com/drugs/DB00309
    ApprovedInvestigationalWithdrawn

    Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).

  10. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence. … Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.